Filtros de búsqueda

Lista de obras de Federica Di Nicolantonio

A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology

scientific article published on 07 March 2019

A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin

scientific article published on 12 December 2019

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.

artículo científico publicado en 2016

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

artículo científico publicado en 2011

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.

artículo científico publicado en 2017

Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas.

scientific article published on May 2003

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.

artículo científico publicado en 2016

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

artículo científico publicado en 2015

Acquired resistance to EGFR-targeted therapies in colorectal cancer

artículo científico publicado en 2014

Adaptive mutability of colorectal cancers in response to targeted therapies

scientific article published on 07 November 2019

Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling.

artículo científico publicado en 2017

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

artículo científico publicado en 2013

An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.

artículo científico publicado en 2016

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

artículo científico publicado en 2010

BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS Mutant Colorectal Cancer

artículo científico publicado en 2016

BRAF V600E is a determinant of sensitivity to proteasome inhibitors

artículo científico publicado en 2013

Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer.

artículo científico publicado en 2018

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

scientific article published on 08 September 2009

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.

artículo científico publicado en 2014

Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.

artículo científico publicado en 2017

Cancer cell adaptation to chemotherapy.

artículo científico publicado en 2005

Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer

artículo científico publicado en 2019

Chemosensitization of solid tumor cells by alteration of their susceptibility to apoptosis.

artículo científico publicado en 2002

Chemosensitization of solid tumors by modulation of resistance mechanisms.

artículo científico publicado en 2002

Circulating Methylated DNA to Monitor the Dynamics of RAS Mutation Clearance in Plasma from Metastatic Colorectal Cancer Patients

scientific article published on 04 December 2020

Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines

artículo científico publicado en 2003

Climbing RAS, the Everest of Oncogenes

artículo científico publicado en 2014

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

artículo científico publicado en 2015

Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor.

artículo científico publicado en 2018

Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C.

artículo científico publicado en 2003

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

artículo científico publicado en 2010

Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.

artículo científico

Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.

artículo científico publicado en 2015

Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer

artículo científico publicado en 2017

EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer

scientific article published on 19 May 2020

Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines

artículo científico publicado en 2006

Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer

artículo científico publicado en 2016

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

artículo científico publicado en 2012

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer

artículo científico publicado en 2017

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.

artículo científico publicado en 2015

Erratum to: Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer

scholarly article published in Targeted oncology

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

scientific article published on 01 July 2015

Evolving neoantigen profiles in colorectal cancers with DNA repair defects

scientific article published on 28 June 2019

Ex vivo characterization of XR11576 (MLN576) against ovarian cancer and other solid tumors

artículo científico publicado en 2004

Ex vivo reversal of chemoresistance by tariquidar (XR9576).

artículo científico publicado en 2004

Exploiting DNA repair defects in colorectal cancer

artículo científico publicado en 2019

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

artículo científico publicado en 2005

Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA).

artículo científico publicado en 2003

Heterogeneity of chemosensitivity of esophageal and gastric carcinoma

artículo científico publicado en 2003

High-dose vitamin C enhances cancer immunotherapy

artículo científico publicado en 2020

Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model

artículo científico publicado en 2014

Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.

artículo científico publicado en 2017

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.

artículo científico publicado en 2017

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.

artículo científico publicado en 2011

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas

artículo científico publicado en 2012

Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.

artículo científico publicado en 2010

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

artículo científico publicado en 2014

Isogenic mutant human cells: a new tool for personalized cancer medicine.

artículo científico publicado en 2010

KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy

artículo científico publicado en 2013

Kinase mutations in cancer: chinks in the enemy's armour?

artículo científico publicado en 2006

Liquid biopsy: monitoring cancer-genetics in the blood

artículo científico publicado en 2013

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

artículo científico publicado en 2016

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.

artículo científico publicado en 2016

Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells.

artículo científico publicado en 2013

Modulation of cerebellar and hepatic nitric oxide synthase by exogenous arginine and endotoxin

artículo científico publicado en 2001

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

artículo científico publicado en 2016

Mouse models of Kras-mutant colorectal cancer: valuable GEMMs for drug testing?

artículo científico publicado en 2013

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

artículo científico publicado en 2009

Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers

artículo científico

Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies

artículo científico publicado en 2018

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

artículo científico publicado en 2007

Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma

artículo científico publicado en 2003

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

artículo científico publicado en 2009

PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs

artículo científico publicado en 2015

Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer

artículo científico publicado en 2017

Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer

artículo científico publicado en 2019

Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus

artículo científico publicado en 2006

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells

artículo científico publicado en 2014

RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer

artículo científico publicado en 2020

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.

artículo científico publicado en 2018

Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer

artículo científico publicado en 2018

Rapid up-regulation of cyclooxygenase-2 by 5-fluorouracil in human solid tumors.

artículo científico publicado en 2005

Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase

artículo científico publicado en 2018

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies.

artículo científico publicado en 2018

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses

artículo científico publicado en 2008

Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution

artículo científico

Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung.

artículo científico publicado en 2016

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

artículo científico publicado en 2014

Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-Ras(G13D).

artículo científico publicado en 2009

Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma

artículo científico publicado en 2020

TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells

artículo científico publicado en 2014

Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels

artículo científico publicado en 2013

Targeted therapies: Tivantinib--a cytotoxic drug in MET inhibitor's clothes?

artículo científico publicado en 2013

Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia

artículo científico publicado en 2011

Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation

artículo científico publicado en 2018

The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination

artículo científico publicado en 2015

The effect of imatinib mesylate (Glivec) on human tumor-derived cells

artículo científico publicado en 2006

The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples.

artículo científico publicado en 2004

The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours

artículo científico publicado en 2004

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets

artículo científico publicado en 2015

Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.

artículo científico publicado en 2010

Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers

artículo científico publicado en 2011

Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor.

artículo científico publicado en 2017

Transfection and DNA-mediated gene transfer

artículo científico publicado en 2011

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer

artículo científico publicado en 2015

Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer

artículo científico

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

artículo científico publicado en 2012

Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer

artículo científico publicado en 2002

VEGF blockade enhances the antitumor effect of BRAFV600E inhibition.

artículo científico publicado en 2017

Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.

artículo científico publicado en 2015

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

artículo científico publicado en 2008

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda